Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Study of DSP-9632P Transdermal Formulation in Healthy Adults and Elderly
jRCT2071210088Phase 1Completed
- Sponsor
- Sumitomo Pharma
- Start
- Oct 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of DSP-9632P in levodopa-induced dyskinesia (LID) (8 arms), sponsored by Sumitomo Pharma. Primary endpoints: Safety endpoints and Pharmacokinetics endpoints. Started Oct 2021; status: completed.
02
Drugs
DSP-9632P
03
Conditions
levodopa-induced dyskinesia (LID)
Beyond the preview
Go deeper on jRCT2071210088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071210088.